Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Germany's Merck Says Erbitux Meets Endpoints in China Phase III Trial

publication date: Apr 25, 2016
Merck KgaA of Germany said Erbitux met its primary endpoint in a China Phase III trial among patients with RAS wild-type metastatic colorectal cancer (mCRC). According to the company, Erbitux increased progression-free survival (PFS) significantly. Erbitux was added to FOLFOX chemotherapy and compared to FOLFOX alone. Specific data from the trial were not included in the company's release, but will be made public at an upcoming scientific meeting. More details....

Stock Symbol: (Xetra: MRK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital